试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-26
The Use of Nutropin Depot in HIV-infected Adult Males
编号:NCT00286676登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:Nutropin、Oral Glucose Tolerance Test、Dual Energy X-ray Absorptiometry (DEXA)、Computed Tomography (CT) Scan
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-26
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
编号:NCT03334487登记状态:入组前撤回企业 / 申办者:AbbVie
药物 / 成分:Dexamethasone、Rovalpituzumab tesirine
登记的停止原因(原文):Strategic considerations
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-26
Intranasal Oxytocin and Food Intake in Obese Adolescents
编号:NCT03497988登记状态:入组前撤回企业 / 申办者:Shana McCormack, MD
药物 / 成分:Syntocinon、Placebo
登记的停止原因(原文):Grant proposal not funded, study has been withdrawn with IRB
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-26
Pre-induction Analgesia: Multimodel Regimen vs Aceteminophen for Post Ureteroscopy Pain
编号:NCT03549611登记状态:入组前撤回企业 / 申办者:Kevin J Flynn MD
药物 / 成分:Multimodal Oral Drug Regimen、Acetaminophen
登记的停止原因(原文):elected not to proceed with the study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-24
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
编号:NCT03316729登记状态:入组前撤回企业 / 申办者:Daiichi Sankyo
药物 / 成分:DS-9231、Placebo
登记的停止原因(原文):Product development cancelled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-21
Providing Access to Cord Blood Units for Transplants
编号:NCT01479582登记状态:入组前撤回企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Access to unlicensed cord blood units
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-21
Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
编号:NCT03234842登记状态:入组前撤回企业 / 申办者:University of Florida
药物 / 成分:Proton Beam Therapy、Photon Radiation Therapy、Chemotherapy
登记的停止原因(原文):non-accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-20
Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant
编号:NCT03026023登记状态:入组前撤回企业 / 申办者:Raymond T. Chung, MD
药物 / 成分:Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
登记的停止原因(原文):moved forward with another protocol utilizing pan genotypic treatment once it became commercially available and FDA approved
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-20
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
编号:NCT03093740登记状态:入组前撤回企业 / 申办者:Massachusetts General Hospital
药物 / 成分:Zepatier、Zepatier plus Sofosbuvir
登记的停止原因(原文):Withdrew IRB application, never approved and no subjects enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-19
Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain
编号:NCT02311777登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:Pregabalin、Ketamine、Placebo
登记的停止原因(原文):Preoperative period is very short time
查看官方原始记录 ↗